10.01.2023 13:20
In just one year, Alentis Therapeutics has completed the first phase of its first-in-human trial for its lead program, ALE.F02, currently in development for the treatment of advanced kidney, lung and liver fibrosis. The study found ALE.F02 to be well tolerated in healthy volunteers at all doses with a good safety profile and demonstrated initial evidence of on-target biological activity.